Lisanti Capital Growth LLC Has $1.09 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Lisanti Capital Growth LLC raised its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 51.2% in the fourth quarter, Holdings Channel reports. The firm owned 51,915 shares of the company’s stock after acquiring an additional 17,585 shares during the quarter. Lisanti Capital Growth LLC’s holdings in SI-BONE were worth $1,090,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in SI-BONE by 48.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,435 shares of the company’s stock worth $158,000 after acquiring an additional 2,437 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in SI-BONE by 2.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 678,360 shares of the company’s stock valued at $14,408,000 after buying an additional 17,449 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of SI-BONE by 1.6% in the third quarter. Assenagon Asset Management S.A. now owns 218,325 shares of the company’s stock valued at $4,637,000 after buying an additional 3,335 shares during the last quarter. Barclays PLC boosted its stake in shares of SI-BONE by 63.2% during the 3rd quarter. Barclays PLC now owns 24,286 shares of the company’s stock worth $516,000 after acquiring an additional 9,402 shares during the period. Finally, Impax Asset Management Group plc increased its holdings in shares of SI-BONE by 35.7% during the 3rd quarter. Impax Asset Management Group plc now owns 475,343 shares of the company’s stock worth $10,096,000 after acquiring an additional 125,000 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, February 27th. Morgan Stanley decreased their price target on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday. Truist Financial restated a “buy” rating and set a $24.00 price objective (down from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $27.00 target price on shares of SI-BONE in a research report on Tuesday. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of SI-BONE in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE has a consensus rating of “Buy” and a consensus price target of $27.29.

Insiders Place Their Bets

In related news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now owns 205,516 shares in the company, valued at approximately $3,175,222.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other SI-BONE news, insider Anthony J. Recupero sold 3,307 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $15.50, for a total transaction of $51,258.50. Following the completion of the transaction, the insider now owns 252,453 shares of the company’s stock, valued at $3,913,021.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Anshul Maheshwari sold 2,425 shares of SI-BONE stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares in the company, valued at $3,175,222.20. The disclosure for this sale can be found here. Insiders have sold 11,905 shares of company stock worth $190,273 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.

SI-BONE Price Performance

Shares of NASDAQ SIBN traded up $1.20 during midday trading on Tuesday, reaching $15.68. The company’s stock had a trading volume of 595,426 shares, compared to its average volume of 432,549. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.15 and a current ratio of 9.01. The company has a market cap of $646.02 million, a P/E ratio of -13.54 and a beta of 1.24. The business’s 50 day moving average price is $15.87 and its two-hundred day moving average price is $18.02. SI-BONE, Inc. has a fifty-two week low of $13.96 and a fifty-two week high of $29.51.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $38.86 million during the quarter, compared to analysts’ expectations of $38.60 million. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. On average, analysts forecast that SI-BONE, Inc. will post -0.98 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.